NCT07284264 · RECRUITING
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
This study is testing a two-step early detection system for Alzheimer's disease. Step one uses a questionnaire, a digital cognitive test, and a risk prediction model to flag people who may be at risk. Step two checks blood-based biomarkers to confirm whether Alzheimer's pathology is present. This is an observational study — it is testing a detection method, not a drug or treatment, and the approach is not yet proven or in clinical use.
You may qualify if
- adults aged 50 and above;
- living in community for at least one year and having established medical records;
- denying a history of cognitive disorders (mild cognitive impairment, dementia, Alzheimer's disease, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.);
- agreeing to participate in the study;
- individual or their relatives can communicate normally in Chinese.
- high-risk groups for dementia（including:1. Complaints of cognitive decline and/or statements by the informant;2. History of AD in first-degree relatives;3. Known ApoE e4 carrier.）
You're excluded if
- Self-reporting or confirmation through inquiry indicates the presence of severe mental disorders, such as bipolar disorder or schizophrenia, etc.
- Having a disease that makes it impossible to complete the cognitive assessment.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-12-16